TCI Wealth Advisors’s CytomX Therapeutics CTMX Stock Holding History

TCI Wealth Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-100	Closed	-$2K	–	1378
2017 Q3	$2K	Buy	+100	New	+$1.56K	﹤0.01%	944

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

TCI Wealth Advisors's CTMX Position: Q4 2017 in Review

TCI Wealth Advisors sold out of CytomX Therapeutics (CTMX) in Q4 2017, closing a stake of 100 shares — an estimated $2K sold.

TCI Wealth Advisors first reported a position in CTMX in Q3 2017 and held it in 1 quarter. The position peaked at $2K in Q3 2017. 119 funds tracked by Wall St. Rank hold CTMX as of Q4 2017.

TCI Wealth Advisors reported no remaining CytomX Therapeutics position as of Q4 2017 after selling out during the quarter.
TCI Wealth Advisors sold 100 CytomX Therapeutics shares in Q4 2017, an estimated $2K.
TCI Wealth Advisors first reported a position in CytomX Therapeutics in Q3 2017 and held it in 1 quarter.
TCI Wealth Advisors's CytomX Therapeutics position peaked at $2K in Q3 2017.
119 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2017.

Based on TCI Wealth Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.